Why is the T-cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Pathway a Promising Cancer Treatment Target?

Why is the T-cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Pathway a Promising Cancer Treatment Target? is organized by Med Learning Group.,Release Date: May 20, 2022,Expiration Date: May 20, 2023,Program Overview:,This enduring activity will focus on the T-cell Immunoreceptor with Ig and ITIM Domains (TIGIT).,,Learning Objectives:,• Evaluate the immunomodulatory activity of TIGIT in anti-cancer immunity,• Assess the anti-tumor effects of dual blockade of TIGIT and ICIs,• Interpret evidence from clinical trials assessing the efficacy, safety, and tolerability of emerging TIGIT inhibitor–ICI combinations with different mechanisms of action for the treatment of patients with advanced solid tumors